Current alternatives of pulmonary arterial hypertension treatment

1.Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327(2): 76-81.

2.Groves BM, Badesch DM, Turkevich D et al. Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension with efficacy of treatment with calcium channel blockers and survival. In: Weir K (ed). Ion flux in pulmonary vascular control. New York: Plenum Press 1993: 317-330.

3.Schrader BJ, Invar S, Kaufmann L et al. Comparison of the effect of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992; 29: 1060-1064.

4.Sitbon O, Hubert M, Jagot JL et al. Inhaled nitric oxide as a screening agent for safety identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265-270.

5.Opitz CF, Wensel R, Bettmann M et al. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003; 24: 356-365.

6.Sitbon O, Hubert M, Ioos V et al. Who benefits from long-term calcium-channel blockers therapy in primary pulmonary hypertension? Am J Respir Crit Care Med 2003; 167: A440.

7.Frank H, Mlczoch, Huber K et al. The effect of anticoagulant therapy in primary and anorectic drug-included pulmonary hypertension. Chest 1997; 112(3): 714-421.

8.Sandoval J, Gaspar J, Pulido T et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilatator treatment. J Am Coll Cardiol 1998; 32: 297-304.

9.Hosenpud JD, Bennett L E et al. The registry of the International society for Heart and Lung Transplantation: Seventeenth official report 2000. J Heart Lung Transplant 2000; 19(10): 909-931.

10.Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334(5): 296-302.

11.Higenbottam T. Treatment of pulmonary hypertension by inhaled delivery. New York: The Parthenon Publishing Group 1999: 9-17.

12.Rubin LJ, Mendoza J, Hood M et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of

randomized trial. Ann Intern Med 1990; 112(7): 485-491.

13.Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum disease. A randomized, controlled trial. Ann Intern Med 2000; 132(6): 425-434.

14.McLaunghlin VV, Gaine SP, Barts RJ et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003; 41(2): 293-299.

15.Simonneau G, Barts RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertsion. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165(6): 800-804.

16.Okano Y, Yoshioka T, Schimouchi A et al. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997; 349(9062): 1365.

17.Galie N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J 2002; 20(4): 1037-1049.

18.Saji T, Ozawa Y, Ishikita T et al. Short-term hemodynamic effects of new oral PGI 2 analogue, beraporost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996; 78(2): 244-247.

19.Nagaya N, Uematsu M, Okano Y et al. Effects of beraprost podium, an oral prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999; 34(4):1188-1192.

20.Galie N, Hubert M, Vachiery JL et al. Effect of beraprost sodium, an oral prostacyclin analogue, in patinets with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-1502.

21.Barts RJ, McGoon M, McLaughlin VV et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.

22.Krause W, Krais T. Pharmacokinetics and phramacodynamics of the prostacyclin analogue iloprost in man. Rur J Clin Pharmacol 1986; 30(1): 61-68.

23.Hoeper MM, Olschewski H, Ghofrani HA et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH Study Group. J Am Coll Cardiol 2000; 35(1): 176-182.

24.Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002; 347(5): 322-329.

25.Hoeper MM, Schwarze M, Ehlerging S et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342(25): 1866-1870.

26.Yanagisawa M. The endothelin system. A new target for therapeutic intervention. Circulacion 1994; 89(3): 1320-1322.

27.Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346(16): 869-903.

28.Barts R, Langleben D, Frost A et al. Sitaxsentan, a selective ETA receptor antagonist, improves exercise capacity and NYHA functional class in pulmonary arterial hypertension (abstr). Am J Respir Crit Care Med 2003; 167: A440.

29.Barts R, Langleben D, Frost A et al. Sitaxsentan, a selective ETA receptor antagonist, improves cardiopulmonary hemodynamics in pulmonary hypertension (abstr). Am J Respir Crit Care Med 2003; 167: A273.

30.Rubin LJ, Galie N, Badesch BD et al. Ambisertan improves exercise capacity and clinical measures in pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2004. (v tisku)

31.Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000; 343(18): 343-1342.

32.Bhatia S, Frantz RP, Severson CJ et al. Immediate and long-term hemodynamic and clinical effects of sildenafil in patient with pulmonary arterial hypertension receiving vasodilaror therapy. Mayo Clin Proc 2003; 78(10): 1207-13.

33.Michelakis ED, Tymchak W, Noga M et al. Long- term treatment with oral sildenafil safe and improves functional capacity and hemodynamics in patient with pulmonary arterial hypertension. Circulation 2003; 108(17): 2006-2069.

34.Sastry BKS, Narasimhan C, Reddy NK et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo–controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43(7): 1149-1153.

35.Nagaya N. Short–term oral administration of L-arginin improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med 2001; 163(4): 887-891.

36.Hubert M, Barst R, Robbins I et al. Safety and efficacy of bosentan combined with epoprostenol in patients with severe pulmonary arterial hypertension (abstr). Am J Respir Crit Care Med 2003; 167: A441.

37.Ghofrani HA, Rose F, Schermuly RT et al. Oral sidenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42(1): 158-164.